Medical devices; revocation of cardiac pacemaker registry. Food and Drug Administration, HHS. Final rule

    Federal Register
    |September 30, 2000
    PubMed

    Insights

    The Food and Drug Administration (FDA) is revoking the cardiac pacemaker registry requirement. This change eliminates duplicative reporting for pacemaker device performance tracking and Medicare administration.

    Area of Science:

    • Medical Device Regulation
    • Public Health Policy

    Background:

    • A cardiac pacemaker registry was mandated by the Deficit Reduction Act of 1984.
    • The registry required physicians and service providers to submit data for pacemaker device implantation, removal, or replacement.
    • Data was used by the FDA for performance tracking and by HCFA for Medicare administration.

    Purpose of the Study:

    • To implement a 1996 congressional act to repeal an unnecessary medical device reporting requirement.
    • To revoke the regulation mandating the cardiac pacemaker registry.
    • To eliminate duplicative and unnecessary reporting burdens.

    Main Methods:

    • Issuance of a final rule by the Food and Drug Administration (FDA).
    • Revocation of a previously established regulation.
    • Removal of data submission requirements for cardiac pacemaker devices and leads.

    Main Results:

    • The cardiac pacemaker registry requirement has been officially revoked.
    • Physicians and service providers are no longer required to submit data to the registry.
    • Elimination of duplicative reporting for medical device oversight.

    Conclusions:

    • The FDA's final rule removes an outdated and redundant reporting requirement.
    • This action streamlines medical device oversight and reduces administrative burden.
    • Focus shifts to more efficient methods for tracking pacemaker device performance and safety.

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    Drug Regulation01:25

    Drug Regulation

    Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
    Good Manufacturing Practices01:26

    Good Manufacturing Practices

    Good Manufacturing Practices (GMP) constitute a foundational set of guidelines that ensure the production of safe, consistent, and high-quality products, particularly in industries such as pharmaceuticals, biotechnology, and food processing. These protocols encompass all aspects of production, from the sourcing of raw materials to the final distribution of the finished product.A core pillar of GMP is stringent hygiene and sanitation across all production environments. This includes routine...
    Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

    Clinically Relevant Drug Product Specifications: Methods of Establishment

    Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
    Standards of Care II01:19

    Standards of Care II

    Nurses bear specific legal responsibilities under several federal statutes, including:
    Regulation of Heart Rates01:31

    Regulation of Heart Rates

    The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
    The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...